CLOVER score to find hidden cancer in people with venous blood clots

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study applies the machine-learning CLOVER score to two cohorts: a retrospective group of adults with objectively confirmed deep vein thrombosis or pulmonary embolism from 2000–2022 and a prospective group enrolled from December 2025 to December 2027. Patients from the centers that developed the model are excluded from the retrospective cohort, and required clinical and laboratory variables are extracted from electronic health records using a standardized form. The CLOVER-Web tool will be used to calculate each patient’s risk and the model’s discrimination for occult cancer will be measured. Clinician satisfaction with the web-based implementation will also be recorded to gauge usability in routine practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years.
* Objectively confirmed acute symptomatic venous thromboembolism (deep vein thrombosis and/or pulmonary embolism).
* Ability to provide written or electronic informed consent.

Exclusion Criteria:

* Suspicion of cancer during the initial diagnostic evaluation for VTE.
* Participation in another interventional study that may interfere with outcomes.
* Inability or refusal to provide informed consent.

Where it's running

• Hospital Clínic
  Barcelona, Barcelona, Spain Recruiting
• Hospital Universitario Infanta Leonor
  Madrid, Madrid, Spain Recruiting
• Hospital Universitario La Paz
  Madrid, Madrid, Spain Recruiting
• Hospital Universitario Príncipe de Asturias
  Madrid, Madrid, Spain Recruiting
• Hospital Universitatio del Sureste
  Madrid, Madrid, Spain Recruiting
• Hospital Universitario de Móstoles
  Madrid, Madrid, Spain Recruiting

Study contacts

• Principal investigator: Anabel Franco-Moreno, MD, PhD — Hospital Universitario Infanta Leonor
• Study coordinator: Anabel Franco Moreno, MD, PhD
• Email: afranco278@hotmail.com
• Phone: +34686102661

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization

  This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.

  Recruiting University of Monastir · Monastir · NCT07863115

• Pulmonary Embolism Registry from Emergency Care to Long-Term Follow-Up

  This registry follows adults with acute pulmonary embolism to see how care is given in the real world and what happens over time.

  Recruiting at 16 sites Azienda Ospedaliero-Universitaria Careggi · Bagno a Ripoli, Tuscany and 15 other locations · NCT07855679

• YKYY033 Injection safety and tolerability in adults

  This study tests whether a single dose of YKYY033 injection is safe and tolerable in healthy adults aged 18–55.

  Recruiting Phase 1 Youcare Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality · NCT07786779

• Blood-clot prevention with REGN7508 and REGN9933 in people with PICC lines

  This study tests whether REGN7508 and REGN9933 can help prevent blood clots in people who have a PICC line.

  Recruiting Phase 3 Regeneron Pharmaceuticals · Tbilisi · NCT07697599

• Treatment and prevention of blood clots in adults with cancer

  This study tests REGN7508 against apixaban to see if it can treat and prevent blood clots in adults with or without cancer, including those with cancer-related clots in the legs and lungs.

  Recruiting at 12 sites Phase 3 Regeneron Pharmaceuticals · Hialeah, Florida and 13 other locations · NCT07493304

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.